Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 9/20 | 0.55 |
| ▸ | PIK3CG | P48736 | 7/20 | 0.55 |
| ▸ | PIK3CB | P42338 | 6/20 | 0.55 |
| ▸ | PIM1 | P11309 | 6/20 | 0.55 |
| ▸ | GSK3B | P49841 | 6/20 | 0.55 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.55 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | CIT | O14578 | 1/20 | 0.39 |
| ▸ | IKBKB | O14920 | 3/20 | 0.38 |
| ▸ | CHUK | O15111 | 3/20 | 0.38 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2214455 | 0.85 | PIK3CD (0.58) | PIK3CDPIK3CGPIK3CBPIM1GSK3B | |
| SCHEMBL458973 | 0.81 | PIK3CD (0.44) | PIK3CDPIK3CGPIK3CBPIM1GSK3B | |
| SCHEMBL1251740 | 0.81 | PIK3CD (0.76) | PIK3CDPIK3CGPIK3CBPIM1GSK3B | |
| SCHEMBL459341 | 0.79 | PIK3CD (0.56) | PIK3CDPIK3CGPIK3CBPIM1GSK3B | |
| SCHEMBL2212654 | 0.79 | PIK3CD (0.45) | PIK3CDPIK3CGPIK3CBPIM1GSK3B | |
| SCHEMBL12577079 | 0.79 | CIT (0.40) | PIK3C3GRM5CITIKBKBCHUK | |
| SCHEMBL2215238 | 0.78 | PIK3CD (0.43) | PIK3CDPIK3CGPIK3CBPIM1GSK3B | |
| SCHEMBL2215542 | 0.78 | TSHR (0.46) | PIK3CDPIK3CGPIK3CBPIM1GSK3B | |
| SCHEMBL2214706 | 0.77 | PIK3CD (0.55) | PIK3CDPIK3CGPIK3CBPIM1GSK3B | |
| SCHEMBL461973 | 0.76 | PIK3CD (0.61) | PIK3CDPIK3CGPIK3CBPIM1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2507226-A1 | NOVEL COMPOUNDS | Glaxo Group Limited (GB) | 2012-10-10 | — | — | EP | claimed |
| US-20120238571-A1 | INDAZOLE DERIVATIVES AS PI 3-KINASE | GLAXO GROUP LIMITED (GB) | 2012-09-20 | — | — | US | claimed |
| US-20120238559-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-09-20 | — | — | US | claimed |
| WO-2011067364-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2011-06-09 | — | — | WO | claimed |
| US-9326987-B2 | Indazole derivatives for use in the treatment of influenza virus infection | GLAXO GROUP LIMITED (GB) | 2016-05-03 | — | — | US | disclosed |
| US-9326987-B2 | Indazole derivatives for use in the treatment of influenza virus infection | GLAXO GROUP LIMITED (GB) | 2016-05-03 | — | — | US | disclosed |
| EP-2613781-A1 | INDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF INFLUENZA VIRUS INFECTION | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2013-07-17 | — | — | EP | disclosed |
| US-20130165433-A1 | Novel Use | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-06-27 | — | — | US | disclosed |
| US-20130165433-A1 | Novel Use | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-06-27 | — | — | US | disclosed |
| EP-2507226-A1 | NOVEL COMPOUNDS | Glaxo Group Limited (GB) | 2012-10-10 | — | — | EP | disclosed |
| US-20120238559-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-09-20 | — | — | US | disclosed |
| US-20120238559-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-09-20 | — | — | US | disclosed |
| WO-2012032065-A1 | INDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF INFLUENZA VIRUS INFECTION | GLAXO GROUP LIMITED (GB) | 2012-03-15 | — | — | WO | disclosed |
| WO-2011067364-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2011-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165433-A1 | Novel Use | HAVCR2, MAVS, ENTPD5 | PIK3CD 2938/4885PIK3CG 2718/4885PIK3CB 1706/4885 |
| US-20120238559-A1 | NOVEL COMPOUNDS | PIK3CA, PIK3CD, PIK3C2B | PIK3CD 2/4885PIK3CG 9/4885PIK3CB 4/4885 |
| US-20120238571-A1 | INDAZOLE DERIVATIVES AS PI 3-KINASE | PI4KA, PIP4K2B, PI4KB | PIK3CD 11/4885PIK3CG 15/4885PIK3CB 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.